ArticleOncotarget2018

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Martina Bonechi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.